The human microbiome refers to the community of microorganisms living in association with the human body. These microbiota include bacteria, fungi, viruses and protozoa that inhabit human body sites such as the gastrointestinal tract, urogenital tract, oral cavity and skin. The microbiota play a key role in human physiology, metabolism, immunity and protection from pathogens through mechanisms like colonization resistance. Dysbiosis or imbalance in the microbial composition can be associated with human health conditions like obesity, diabetes, inflammatory bowel disease and cancer. Products targeting the microbiome leverage microbiota-modulating approaches like prebiotics, probiotics and small molecule therapies to treat diseases related to microbiome dysbiosis.
The global Human Microbiome Market is estimated to be valued at US$ 4248.55 Mn in 2023 and is expected to exhibit a CAGR of 24% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Microbiome dysbiosis has emerged as a major driver of various chronic health conditions. Research suggests altered gut microbiota composition is associated with metabolic disorders like obesity and diabetes. Products targeting the gut-brain axis through modulation of the gut microbiota hold potential for management of neurological and mental health issues as well. Leading players in the human microbiome market are developing microbiota-based therapies targeting dysbiosed microbial ecosystems in specific disease conditions. Continued advances in microbiome research coupled with growing understanding of the role of microbiota in human health are expected to further validate microbiome-directed approaches and accelerate growth of the human microbiome market over the forecast period.
Segment Analysis
The global human microbiome market is dominated by the therapeutic sub segment due to the growing research and development in microbiome based drugs and therapies to treat various diseases. Microbiome based therapies are gaining popularity over traditional drugs due to their targeted treatment approach and lesser side effects.
Key Takeaways
The Global Human Microbiome Market Demand is expected to witness high growth during the forecast period from 2023 to 2030. The market size is projected to grow from US$ 4248.55 Mn in 2023 Mn by 2030 at a CAGR of 24%.
Regional analysis: North America region is expected to dominate the global human microbiome market during the forecast period. This is attributed to presence of major market players, growing funding for microbiome research by pharmaceutical and biotech companies as well as government bodies in the US and Canada.
Key players: Key players operating in the human microbiome market are Seres Therapeutics, Biomesense, Microbiotica, Infant Bacterial Therapeutics AB, Vedanta Biosciences, Inc., Second genome therapeutics, 4D Pharma Ferring Inc, Enterome, BiomX, MaaT Pharma, Azitra, Illumina, Inc, Locus Biosciences, Inc, Finch Therapeutics Group, Inc, Rebiotix Inc, Servatus Ltd, Microbiome Research Pvt. Ltd, AOBiome, Axial Therapeutics, Inc, Biomica. These players are focusing on new product launches, expansions, partnerships and acquisitions to strengthen their market presence in the lucrative human microbiome market.
Explorer more information on this topic, Please visit-
